Isaac E. Ciechanover is CEO at Atara Biotherapeutics, Inc. (ATRA). They have made 5 open-market trades across 1 company since 2017, most recently 2019-05-30.
CIK 0001612096
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ATRA | 290,687 | $2.8M |
Shares reported on the most recent Form 4, priced at the 2019-05-31 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ATRA | SELL | 2019-05-29 | 2019-05-31 | $23.09 | $135K | -0.6% | -11.1% | -37.3% |
| ATRA | SELL | 2019-03-28 | 2019-04-01 | $38.66 | $302K | -9.6% | -18.4% | -51.0% |
| ATRA | SELL | 2019-01-23 | 2019-01-25 | $35.06 | $273K | +7.6% | +16.7% | -6.6% |
| ATRA | SELL | 2018-01-22 | 2018-01-24 | $34.58 | $1.7M | -2.2% | +31.0% | +18.5% |
| ATRA | SELL | 2017-07-24 | 2017-07-26 | $16.49 | $91K | +0.0% | -10.9% | -3.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.